Abstract
The human immunodeficiency virus type-1 (HIV-1) is the etiologic agent for acquired immunodeficiency syndrome (AIDS), which has reached pandemic proportions in recent years. A second immunodeficiency virus (designated HIV-2), which is serologically distinct from HIV-1, was later isolated from West African patients with AIDS. Research efforts have intensified in an attempt to discover new therapeutic modalities for the treatment of this fatal disease. The complex replication process of the HIV in its host cell offers many potential target points for therapeutic intervention. Examples include viral attachment and uncoating, reverse transcription of the viral genome, proviral DNA integration into the host cell DNA and subsequent transcription and translation of this genetic material into viral proteins. As these viral proteins in turn undergo processing, e.g., protein glycosylation, which then leads to the assembly and release of progeny virus particles, additional target points are obvious.
Chapter PDF
Similar content being viewed by others
Keywords
- Human Immunodeficiency Virus
- Human Immunodeficiency Virus Type
- Reverse Transcriptase Activity
- Pentosan Polysulfate
- Antileukemic Activity
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
F. Barre-Sinoussi, J. C. Chermann, J. Rey, M. T. Nugebe, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vezinek-Brun, C. Rouzioux, W. Rozenbaum, and L. Montagnier, Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome, Science 220:868 (1983).
F. Clavel, D. Guetard, F. Brun-Vezinet, S. Chamaret, M. A. Rey, M. O. Santos-Ferreira, A. G. Laurent, C. Dauguet, C. Katlama, C. Rouzioux, D. Klatzmann, J. L. Champalimaud, and L. Montagnier, Isolation of a new human retrovirus from West African patients with AIDS, Science 233:343 (1986).
M. Guyader, M. Emerman, P. Sonigo, F. Clavel, L. Montagnier, and M. Alizon, Genome organization and transactivation of the human immunodeficiency virus type 2, Nature (London) 326:662 (1987).
P. S. Sarin, Molecular pharmacologic approaches to the treatment of AIDS, Ann. Rev. Pharmacol. 28:411 (1988).
M. S. Hirsch, Chemotherapy of human immunodeficiency virus infections: Current practice and future prospects, J. Infect. Dis. 161:845 (1990).
K. Ono, H. Nakane, F. Barre-Sinoussi, and J. C. Chermann, Differential inhibition of various mammalian DNA polymerase activities by ammonium-21-tungsto-9-antimoniate (HPA 23), Eur. J. Biochem. 176:305 (1988).
K. Ono, H. Nakane, and M. Fukushima, Differential inhibition of various deoxyribonucleic and ribonucleic acid polymerases by suramin, Eur. J. Biochem 172:349 (1988).
S. F. Le Grice, R. Zehnle, and J. Mous, A single 66-kilodalton polypeptide processed from the human immunodeficiency virus type 2 pol polyprotein in Escherichia coli displays reverse transcriptase activity, J. Virol. 62:2525 (1988).
A. L. De Vico, T. D. Copeland, F. Di Marzo Veronese, S. Oroszlan, R. C. Gallo, and M. G. Sarngadharan, Purification and partial characterization of human immunodeficiency virus type 2 reverse transcriptase, AIDS Res. Hum. Retroviruses 5:51 (1989).
A M. Barber, A Hizi, J. V. Maizel, Jr., and S. H. Hughes, HIV-1 reverse transcriptase: Structure predictions for the polymerase domain, AIDS Res. Hum. Retroviruses 6:1061 (1990).
A Hizi, R. Tal, and S. H. Hughes, Mutational analysis of the DNA polymerase and ribonuclease H activities of Human Immunodeficiency Virus type 2 reverse transcriptase expressed in Escherichia coli, Virology 180:339 (1991).
Manuscript in preparation.
H. Varmus, Retroviruses, Science 240:1427 (1988).
F. D. Di Marzo Veronese, T. D. Copeland, A L. De Vico, R. Rahman, S. Oroszlan, R. C. Gallo, and M. G. Sarngadharan, Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV, Science 231:1289 (1986).
W. G. Farmerie, D. D. Loeb, N. C. Casavant, C. A. Hutchinson, III, M. H. Edgell, and R. Swanstrom, Expression and processing of the AIDS virus reverse transcriptase in Escherichia coli, Science 236:305 (1987).
H. Mitsuya, and S. Broder, Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type-III/lymphadenopathy associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides, Proc. Natl. Acad. Sci. USA 83:1911 (1986).
P. Chandra, U. Ebener, and A Götz, Inhibition of oncornaviral DNA polymerase by 5-mercapto polycytidylic acid: mode of action, FEBS Lett. 53:10 (1975).
L. Vrang, and B. Öberg, PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase, Antimicrob. Agents Chemother. 29:867 (1986).
M. L. Sethi, Inhibition of reverse transcriptase activity by benzophenanthridine alkaloids, J. Nat. Prod. 42:187 (1979).
H. M. Temin, and D. Baltimore, RNA-directed DNA synthesis and RNA tumor viruses, Adv. Virus Res. 17:129 (1972).
E. Haslam, T. H. Lilley, Y. Cai, R. Martin, and D. Magnolato, Traditional herbal medicines: The role of polyphenols, Planta Med. 55:1 (1989).
P. C. Zamecnik, J. Goodchild, Y. Taguchi, and P. S. Sarin, Inhibition of replication and expression of human T-cell lymphotropic virus type-III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA, Proc. Natl. Acad. Sci. 83:4143 (1986).
A D. Hoffman, B. Banapour, and J. A Levy, Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions, Virology 147:326 (1985).
G. T. Tan, J. M. Pezzuto, A D. Kinghorn and S. H. Hughes, Evaluation of natural products as inhibitors of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase, J. Nat. Prod. 54:143 (1991).
A Hizi, C. McGill, and S. H. Hughes, Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in E. coli and analysis of mutants, Proc. Natl. Acad. Sci. USA 85:1218 (1988).
A Hizi, R. Tal, and S. H. Hughes, Mutational analysis of the DNA polymerase and ribonuclease H activities of Human Immunodeficiency Virus type 2 reverse transcriptase expressed in Escherichia coli, Virology 180:339 (1991).
R. F. Schinazi, B. F. H. Eriksson, and S.H. Hughes, Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptases, Antimicrob. Agents Chemother. 33:115 (1989).
P. K. Clark, A L. Ferris, D. A Miller, A Hizi, K.-W. Kim, S. M. Deringer-Boyer, M. L. Mellini, A D. Clark, Jr., G. F. Arnold, W. B. Lebherz, III, E. Arnold, G. M. Muschik, and S. H. Hughes, HIV-1 reverse transcriptase purified from a recombinant strain of Escherichia coli, AIDS Res. Human Retroviruses 6:753 (1990).
V. S. Sethi, Base specificity in the inhibition of oncornavirus reverse transcriptase and cellular nucleic acid polymerases by antitumor drugs, Ann. N. Y. Acad. Sci. 284:508 (1977).
G. T. Tan, A D. Kinghorn, S. H. Hughes, and J. M. Pezzuto, Psychotrine and its O-methyl ether are selective inhibitors of human immunodeficiency virus-1 reverse transcriptase, J. Biol. Chem. 35:23529 (1991).
L. Ratner, W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Rafalski, E. A Whitehorn, K. Baumeister, L. Ivanoff, S. R. Petteway, Jr., M. L. Pearson, J. A Lautenberger, T. S. Papas, J. Ghrayeb, N. T. Chang, R. C. Gallo, and F. Wong-Staal, Complete nucleotide sequence of the AIDS virus, HTLV-III, Nature 313:277 (1985).
K. Ono, H. Nakane, M. Fukushima, J.-C. Chermann, and F. Barré-Sinoussi, Inhibition of reverse transcriptase activity by a flavonoid compound, 5,6,7-trihydroxyflavone, Biochem. Biophys. Res. Commun. 160:982 (1989).
W. M. Messmer, M. Tin-Wa, H. H. S. Fong, C. Bevelle, N. R. Farnsworth, D. J. Abraham, and J. Trojanek, Fagaronine, a new tumor inhibitor isolated from Fagara zanthoxyloides Lam. (Rutaceae), J. Pharm. Sci. 61:1858 (1972).
N. Kakiuchi, M. Hattori, T. Namba, M. Nishizawa, T. Yamagishi, and T. Okuda, Inhibitory efect of tannins on reverse transcriptase from RNA tumor viruses, J. Nat. Prod. 48:614 (1985).
W. D. Loomis and J. Battaile, Plant phenolic compounds and the isolation of plant enzymes, Phytochemistry 5:423 (1966).
M. E. Wall, H. Taylor, L. Ambrosio, and K. Davis, Plant antitumor agents III: A convenient separation of tannins from other plant constituents, J. Pharm. Sci. 58:839 (1969).
F. M. Thompson, L. J. Libertini, U. R. Joss, and M. Calvin, Detergent effects on reverse transcriptase activity and on inhibition by rifamycin derivatives, Science 178:505 (1972).
S. Simeon, J. L. Rios, and A Villar, Pharmacological activities of benzophenanthridine and phenanthrene alkaloids, Pharmazie 44:593 (1989).
M. Arisawa, J. M. Pezzuto, C. Bevelle, and G. A. Cordell, Potential anticancer agents XXXI. N-Demethylation of fagaronine, J. Nat. Prod. 47:453 (1984).
R. K. Y. Zee-Cheng, and C. C. Cheng, Preparation and antileukemic activity of some alkoxybenzo[c]phenanthridinium salts and corresponding dihydro derivatives, J. Med. Chem.18:66 (1975).
L. A. Mitscher, Y. H. Park, D. Clark, G. W. Clark, III, P. D. Hammesfahr, W. N. Wu, and J. L. Beal, Antimicrobial agents from higher plants. An investigation of Hunnemannia fumariaefolia pseudoalcoholates of sanguinarine and chelerythrine, Lloydia 41:145 (1978).
F. R. Stermitz, J. P. Gillespie, L. G. Amoros, R. Romero, T. A. Stermitz, K. L. Larson, S. Earl, and J. E. Ogg, Synthesis and biological activity of some antitumor benzophenanthridinium salts, J. Med. Chem. 18:708 (1975).
J. W. Lee, J. O. MacFarlane, R. K. Y. Zee-Cheng, and C. C. Cheng, Inhibition of catechol O-methyltransferase and transfer RNA methyltransferases by coralyne, nitidine, and related compounds, J. Pharm. Sci. 66:986 (1977).
C. C. Cheng, Inhibitors of tRNA O-methyltransferase as possible antineoplastic agents, J. Pharm. Sci. 61:645 (1972).
K. D. Straub, and P. Carver, Sanguinarine, inhibitor of Na-K-dependent ATPase, Biochem. Biophys. Res. Commun. 62:913 (1975).
H. G. Cohen, E. E. Seifen, K. D. Straub, C. Tiefenback, and F. R. Stermitz, Structural specificity of the NaK-ATPase inhibition by sanguinarine, an isoquinoline benzophenanthridine alkaloid, Biochem. Pharmacol. 27:2555 (1978).
J. M. Herbert, J. M. Augereau, J. Gleye, and J. P. Maffrand, Chelerythrine is a potent and specific inhibitor of protein kinase C, Biochem. Biophys. Res. Commun. 172:993 (1990).
V. S. Sethi, and M. L. Sethi, Inhibition of reverse transcriptase activity of RNA-tumor viruses by fagaronine, Biochem. Biophys. Res. Commun. 63:1070 (1975).
V. S. Sethi, Inhibition of mammalian and oncornavirus nucleic acid polymerase activities by alkoxybenzophenanthridine alkaloids, Cancer Res. 36:2390 (1976).
C. A C. Torres, and A Baez, Effects of the antitumor drugs 3-nitrobenzothiazolo[3,2α]quinolinium and fagaronine on nucleic acid and protein synthesis, Biochem. Pharmacol. 35:679 (1986).
M. L. Sethi, Screening of benzophenanthridine alkaloids for their inhibition of reverse transcriptase activity and preliminary report on the structure-activity relationships, Can. J. Pharm. Sci. 16:29 (1981).
M. A Caolo, and F. R. Stermitz, Benzophenanthridinium salt equilibria, Heterocycles 12:11 (1979).
F. R. Stermitz, K. A Larson, and D. K. Kim, Some structural relationships among cytotoxic and antitumor benzophenanthridine alkaloid derivatives, J. Med. Chem. 16:939 (1973).
N. P. S. Bajaj, M. J. McLean, M. J. Waring, and E. Smekal, Sequence-selective, pH-dependent binding to DNA of benzophenanthridine alkaloids, J. Mol. Recognit. 3:48 (1990).
K. Y. Zee-Cheng, and C. C. Cheng, Common receptor-complement feature among some antileukemic compounds, J. Pharm. Sci. 59:1630 (1970).
N. Kakiuchi, M. Hattori, H. Ishii, and T. Namba, Effect of benzo(c)phenanthridine alkaloids on reverse transcriptase and their binding property to nucleic acids, Planta Medica 53:22 (1987).
J. M. Pezzuto, S. K Antosiak, W. M. Messmer, M. B. Slaytor, and G. R. Honig, Interaction of the antileukemic alkaloid, 2-hydroxy-3,8,9-trimethoxy-5-methylbenzo[c]phenanthridine (fagaronine), with nucleic acids, Chem.-Biol. Interact. 43:323 (1983).
R. Nandi, and M. Maiti, Binding of sanguinarine to deoxyribonucleic acids of differing base compositions, Biochem. Pharmacol. 34:321 (1985).
R. Nandi, K. Chaudhuri, and M. Maiti. Effects of ionic strength and pH on the binding of sanguinarine to deoxyribonucleic acid, Photochem. Photobiol. 42:497 (1985).
Y. Kondo, Organic and biological aspects of berberine alkaloids, Heterocycles 4:197 (1976).
M. Cushman, F. W. Dekow, and L. B. Jacobsen, Conformations, DNA binding parameters, and antileukemic activity of certain cytotoxic protoberberine alkaloids, J. Med. Chem. 22:331 (1979).
R. K. Y. Zee-Cheng, K. D. Pauli, and C. C. Cheng, Experimental antileukemic compounds: Coralyne, analogs and related compounds, J. Med. Chem. 17:347 (1974).
R. K. Y. Zee-Cheng, and C. C. Cheng, Tetramethoxydibenzoquinolizinium salts. Preparation and antileukemic activity of some positional and structural isomers of coralyne, J. Med. Chem.19:882 (1976).
J. Kovar, and S. Pavelka, Characterization of binding site of horse liver alcohol dehydrogenase for berberines and auramine O, Collect. Czech. Chem. Commun. 41:1081 (1976).
J. Kovar, J. Stejskal, and L. Matyska, Interaction of yeast alcohol dehydrogenase with protoberberine alkaloids, J. Enzym. Inhib. 1:35 (1985).
S. Kuwano, and K. Yamauchi, Effect of berberine on tyrosine decarboxylase activity of Streptococcus faecalis, Chem. Pharm. Bull. 8:491 (1960).
S. Kuwano, and K Yamauchi, Competition of berberine with pyridoxal phosphate in the tryptophanase system of Escherichia coli, Chem. Pharm. Bull. 8:497 (1960).
M. L. Sethi, Enzyme inhibition VI: Inhibition of reverse transcriptase activity by protoberberine alkaloids and structure-activity relationships, J. Pharm. Sci. 72:538 (1983).
M. L. Sethi, Enzyme inhibition VIII: Mode of inhibition of reverse transcriptase activity by analogues, isomers, and related alkaloids of coralyne, J. Pharm. Sci. 74:889 (1985).
R. K Y. Zee-Cheng, and C. C. Cheng, Interaction between DNA and coralyne acetosulfate, an antileukemic compound, J. Pharm. Sci. 62:1572 (1973).
W. D. Wilson, A N. Gough, J. J. Doyle, and M. W. Davidson, Coralyne. Intercalation with DNA as a possible mechanism of antileukemic action, J. Med. Chem. 19:1261 (1976).
A K. Krey, and F. E. Hahn, Berberine: complex with DNA, Science 166:755 (1969).
M. W. Davidson, I. Lopp, S. Alexander, and W. D. Wilson, The interaction of plant alkaloids with DNA II. Berberinium chloride, Nucleic Acids Res. 4:2697 (1977).
M. L. Sethi, Comparison of inhibition of reverse transcriptase and antileukemic activities exhibited by protoberberine and benzophenanthridine alkaloids and structure-activity relationships, Phytochemistry 24:447 (1985).
Y. C. Wu, Y. F. Liou, S. T. Lu, C. H. Chen, J. J. Chang, and K. H. Lee, Cytotoxicity of isoquinoline alkaloids and their N-oxides, Planta Med. 55:163 (1989).
G. A Cordell, “Introduction to Alkaloids: A Biogenetic Approach,” John Wiley & Sons, Inc., New York, NY, pp. 560–567, (1981).
V. E. Tyler, L. R. Brady, and J. E. Robbers, “Pharmacognosy,” 9th edn., Lea & Febiger, Philadelphia, PA, pp. 209–212, (1988).
E. B. Vedder, A preliminary account of some experiments undertaken to test the efficacy of the Ipecacuanha treatment of dysentery, J. Trop. Med. 14:149 (1911).
A I. Grollman, Emetine in the treatment of intra-abdominal and retroperitoneal non-specific granulomas, Surg. Gynecol. Obstet. 120:792 (1965).
E. Grunberg, and H. N. Prince, Antiviral activity of emetine, 2-dehydroemetine and 2-dehydro-3-noremetine, Antimicrob. Agents Chemother. 6:527 (1966).
A P. Grollman, Inhibitors of protein biosynthesis, J. Biol Chem. 243:4089 (1968).
A P. Grollman, Structural basis for inhibition of protein synthesis by emetine and cycloheximide based on an analogy between ipecac alkaloids and glutarimide antibiotics, Proc. Natl. Acad. Sci. U.S.A. 56:1867 (1966).
A. P. Grollman, Emetine: New uses for an old drug, Ohio State Medical J. 66:257 (1970).
A P. Grollman, Mode of action of emetine: The inhibition of protein synthesis, Pharmacologist 8:190 (1966).
V. Cody, E. Middleton, Jr., and J. B. Harborne, eds., “Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological and Structure-activity Relationships,” Alan R. Liss, Inc., New York (1986).
B. Havsteen, Flavonoids, a class of natural products of high pharmacological potency, Biochem. Pharmacol. 32:1141 (1983).
M. Auf’mkolk, J. Koehrle, R. D. Hesch, and V. Cody, Inhibition of rat liver iodothyronine deiodinase: Interaction of aurones with the iodothyronine ligand-binding site, J. Biol. Chem. 261:11623 (1986).
J. E. Ferrell, P. D. G. Chang-Sing, G. Loew, R. King, J. M. Mansour, and T. E. Mansour, Structure-activity studies of flavonoids as inhibitors of cyclic AMP phosphodiesterase and relationship to quantum chemical indices, Molec. Pharmacol. 16:556 (1979).
E. Middleton, Jr., and P. Ferriola, Effect of flavonoids on protein kinase C: Relationship to inhibition of human basophil histamine release, in: “Plant Flavonoids in Biology and Medicine II: Biochemical, Cellular, and Medicinal Properties,” V. Cody, E. Middleton, Jr., J. B. Harborne, and A Beretz, eds., Alan R. Liss, Inc., New York (1988).
R. T. Borchardt, and J. A Huber, Catechol-O-methyl-transferase. 5. Structure-activity relationships for inhibition by flavonoids, J. Med. Chem. 18:120 (1975).
M. Rossi, L. F. Rickles, and W. A Halpin, The crystal and molecular structure of quercetin: A biologically active and naturally occurring flavonoid, Bioorganic. Chem. 14:55 (1986).
V. Cody, Crystal and molecular structures of flavonoids, in: “Plant Flavonoids in Biology and Medicine II: Biochemical, Cellular, and Medicinal Properties,” V. Cody, E. Middleton, Jr., J. B. Harborne, and A Beretz, eds., Alan R. Liss, Inc., New York, pp. 29–44 (1988).
J. S. Cantrell, Crystal structures, bonding, and hydrogen bonding in flavonoid compounds, in: “Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological and Structure-activity Relationships,” V. Cody, E. Middleton, Jr., and J. B. Harborne, eds., Alan R. Liss, Inc., New York, pp. 391–394 (1986).
J. W. T. Selway, Antiviral activity of flavones and flavans, in: “Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological and Structure-activity Relationships,” V. Cody, E. Middleton, Jr., and J. B. Harborne, eds., Alan R. Liss, Inc., New York, pp 521–536 (1986).
T. N. Kaul, E. Middleton, Jr., and P. L. Ogra, Antiviral effect of flavonoids on human viruses, J. Med. Virol. 15:71 (1985).
Y. Tsuchiya, M. Shimizu, Y. Hiyama, K. Itoh, Y. Hashimoto, M. Nakayama, T. Horie, and N. Morita, Antiviral activity of naturally occurring flavonoids in vitro, Chem. Pharm. Bull. 33:3881 (1985).
Y. Ninomiya, C. Uhsawa, M. Aoyama, I. Umeda, Y. Suhara, and H. Ishitsuka, Antivirus agents, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation, Virology 134:269 (1984).
J. L. Castrillo, D. Vanden Berghe, and L. Carrasco, 3-Methyl-quercetin is a potent and selective inhibitor of poliovirus RNA synthesis, Virology 152:219 (1986).
P. H. Fischer, M. A Apple, and I. Strokon, Quantitative structure-activity analysis of flavonol inhibition of RNA directed vs DNA directed polynucleotide polymerases, Pharmacologist 17:229 (1975).
G. Spedding, A Ratty, and E. Middleton, Jr. Inhibition of reverse transcriptases by flavonoids, Antiviral Res. 12:99 (1989).
K. Ono, H. Nakane, M. Fukushima, J.-C. Chermann, and F. Barré-Sinoussi, Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases, Eur. J. Biochem. 190:469 (1990).
K. Shinozuka, Y. Kikuchi, C. Nishino, A Mori, and S. Tawata, Inhibitory effect of flavonoids on DNA-dependent DNA and RNA polymerases, Experientia 44:882 (1988).
K. Ono, and H. Nakane, Mechanisms of inhibition of various cellular DNA and RNA polymerases by several flavonoids, J. Biochem. (Tokyo) 108:609 (1990).
A Mori, C. Nishino, N. Enoki, and S. Tawata, Cytotoxicity of plant flavonoids against HeLa cells, Phytochemistry 27:1017 (1988).
K. Nose, Inhibition by flavonoids of RNA synthesis in permeable WI-38 cells and of transcription by RNA polymerase II, Biochem. Pharmacol. 33:3823 (1984).
A. Beretz, R. Anton, and J. C. Stoclet, Flavonoid compounds are potent inhibitors of cyclic AMP phosphodiesterase, Experientia 34:1054 (1978).
A. Veckenstedt, I. Béladi, and I. Mucsi, Effect of treatment with certain flavonoids on Mengo virus-induced encephalitis in mice, Arch. Virol. 57:255 (1978).
J. Guttner, A. Veckenstedt, H. Heinecke, and R. Pusztai, Effect of quercetin on the course of Mengo virus infection in immunodeficient and normal mice. A histologic study, Acta Virol. 26:148 (1982).
I. M. Baird, R. E. Hughes, H. K. Wilson, J. E. W. Davies, and A. N. Howard, The effects of ascorbic acid and flavonoids on the occurrence of symptoms normally associated with the common cold, Am. J. Clin. Nutr. 32:1686 (1979).
M. Ito, M. Baba, A. Sato, R. Pauwels, E. De Clercq, and S. Shigetta, Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro, Antiviral Res. 7:361 (1987).
G. Sydow, and H.-P. Krocking, Effect of pentosan polysulfate (SP54) on the reverse transcriptase activity of several retroviruses, Biomed. Biochem. Acta 46:527 (1987).
M. Baba, M. Nakajima, D. Schols, R. Pauwels, J. Balzarini, and E. DeClercq, Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro, Antiviral Res. 9:335 (1988).
P. De Somer, E. De Clercq, A. Billiau, E. Schonne, and M. Claesen, Antiviral activity of polyacrylic and polymethacrylic acids. I. Mode of action in vitro, J. Virol. 2:878 (1968).
H. Nakashima, Y. Kido, N. Kobayashi, Y. Motoki, M. Neushul, and N. Yamamoto, Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae, Antimicrob. Agents Chemother. 31:1524 (1987).
H. Nakashima, T. Matsui, O. Yoshida, Y. Isowa, Y. Kido, Y. Motoki, M. Ito, S. Shigeta, T. Mori, and N. Yamamoto, A new anti-human immunodeficiency virus substance, glycyrrhizin sulfate; endowment of glycyrrhizin with reverse transcriptase inhibitory activity by chemical modification, Jpn. J. Cancer Res. (Gann) 78:767 (1987).
F. M. Hallinan, S. H. S. Lee, and K. R. Rozee, Inhibition of reverse transcriptase by polyvinyl sulfate (PVS), Cancer Biochem. Biophys. 98:97 (1981).
P. S. Sarin, D. Sun, A. Thornton, and W. E. G. Muller, Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy associated virus) by avarol and avarone, J. Natl. Cancer Inst. 78:663 (1987).
Y. Kuchino, S. Nishimura, H. C. Schroder, M. Rottmann, and W. E. G. Muller, Selective inhibition of formation of suppressor glutamine tRNA in Moloney murine leukemia virus-infected NIH-3T3 cells by avarol, Virology 165:518 (1988).
S. Loya, and A. Hizi, The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives, FEBS Lett. 269:131 (1990).
K. Ono, H. Nakane, S. Shimizu, and S. Koshimura, Inhibition of HIV reverse transcriptase activity by asterriquinone and its analogs, Biochem. Biophys. Res. Commun. 174:56 (1991).
H. Higuchi, K. Mori, A. Kato, T. Ohkuma, T. Endo, H. Kaji, and A. Kaji, Antiretroviral activities of anthraquinones and their inhibitory effects on reverse transcriptase, Antiviral Res. 15:205 (1991).
S. Loya, R. Tal, Y. Kashman, and A. Hizi, Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents Chemother. 34:2009 (1990).
R. F. Schinazi, C. K. Chu, J. R. Babu, B. J. Oswald, V. Saalmann, D. L. Cannon, B. F. H. Eriksson, and M. Nasr, Anthraquinones as a new class of antiviral agents against human immunodeficiency virus, Antiviral Res. 13:265 (1990).
M. M. Wick, and G. Fitzgerald, Inhibition of reverse transcriptase by tyrosinase-generated quinones related to levodopa and dopamine, Chem.-Biol. Interact. 38:99 (1981).
H. Nakane, M. Arisawa, A. Fujita, S. Koshimura, and K. Ono, Inhibition of HIV-reverse transcriptase activity by some phloroglucinol derivatives, FEBS Lett. 286:83 (1991).
M. L. Sethi, Inhibition of RNA-directed DNA polymerase activity of RNA tumor viruses by taspine, Can. J. Pharm. Sci. 12:7 (1977).
T. S. Papas, L. Sandhaus, M. A. Chirigos, and E. Furusawa, Inhibition of DNA polymerase of avian myeloblastosis virus by an alkaloid extract from Narcissus tazetta L., Biochem. Biophys. Res. Commun. 52:88 (1973).
K. V. R. Dhananjaya, and A. Antony, Inhibition of avian myeloblastosis virus reverse transcriptase and its associated activities by daunomycin and adriamycin, Ind. J. Biochem. Biophys. 24:265 (1987).
M. A Chirigos, J. W. Pearson, T. S. Papas, W. A Woods, H. B. Wood, Jr., and G. Spahn, Effect of streptonigrin (NSC-45383) and analogs on oncornavirus replication and DNA polymerase activity, Cancer Chemother. Rep. 57:305 (1973).
C. Gurgo, and P. Grandgenett, Different modes of inhibition of purified ribonucleic acid directed deoxyribonucleic acid polymerase of avian myeloblastosis virus by rifamycin SV derivatives, Biochemistry 16:786 (1977).
Y. Hafuri, E. Takemori, K. Oogose, Y. Inouye, S. Nakamura, Y. Kitahara, S. Nakahara, and A Kubo, Mechanism of inhibition of reverse transcriptase by quinone antibiotics. II. Dependence on putative quinone pocket on the enzyme molecule, J. Antibiot. 41:1471 (1988).
Y. Take, Y. Inouye, S. Nakamura, H. S. Allaudeen, and A Kubo, Comparative studies of the inhibitory properties of antibiotics on human immunodeficiency virus and avian myeloblastosis virus reverse transcriptases and cellular DNA polymerases, J. Antibiot. 42:107 (1989).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Tan, G.T., Pezzuto, J.M., Kinghorn, A.D. (1992). Screening of Natural Products as HIV-1 And HIV-2 Reverse Transcriptase (RT) Inhibitors. In: Chu, C.K., Cutler, H.G. (eds) Natural Products as Antiviral Agents. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3414-3_10
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3414-3_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6509-9
Online ISBN: 978-1-4615-3414-3
eBook Packages: Springer Book Archive